Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.021 | 0.7 |
mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.7 |
mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.7 |
mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.7 |
mRNA | piperlongumine:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.011 | 0.7 |
mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |